NewsUpdated 8 min read
RFK Jr.'s peptide policy: what HHS changed for BPC-157 and five other peptides
HHS released a draft policy on October 28, 2026: it will not act against licensed compounding of BPC-157, TB-500, epitalon, KPV, MOTS-c, or semax under strict conditions. It is not FDA approval.
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
On October 28, 2026, the Department of Health and Human Services (HHS), led by Secretary Robert F. Kennedy Jr., released a draft enforcement discretion policy for six peptides: BPC-157, TB-500, epitalon, KPV, MOTS-c, and semax. HHS says it will not take enforcement action against licensed compounding of these six as single-ingredient products, by set routes and under strict conditions. [1] [2] It is a draft, it is not an FDA approval, and it does not put any peptide on the 503A bulks list.
TIME called it "The Peptide Rush Has Begun," and some are calling the moment the great peptide rush. [9] Some early reports also gave a larger number of peptides. The policy's Appendix A lists six, and only six. [2]
What HHS announced
HHS filed a notice of availability for a draft policy titled "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." It was filed for public inspection on October 28, 2026, and was published in the Federal Register on October 30, 2026, under Docket No. HHS-OASH-2026-0496. [1]
The policy is signed by the Secretary of HHS, not issued by FDA. HHS says it "does not intend to take enforcement action" against a state-licensed pharmacy, federal facility, or licensed physician that compounds a drug product from one of the six peptide bulk substances in Appendix A, when all of the policy's conditions are met. [2] It does not mention 503B outsourcing facilities.
HHS also says the policy does not establish any rights for any person and is not binding on HHS or the public. HHS may revisit it, in whole or in part, if a safety signal or product quality issue arises. It applies only until each peptide is addressed in a final rule on whether it is included on the 503A bulks list. [2]
The six peptides and their allowed routes
Appendix B limits each peptide to a specific form and route. A product outside these limits is outside the policy. [2]
| Peptide | Form named in Appendix B | Allowed routes | Regulatory history | | ------------------------------ | ------------------------ | ---------------------------------------------------------------- | ----------------------------------------- | | BPC-157 | BPC-157 acetate | Subcutaneous, intramuscular, oral, topical | BPC-157 timeline | | TB-500 | TB-500 acetate | Subcutaneous or intramuscular injection | TB-500 timeline | | Epitalon | Epitalon acetate | Subcutaneous or intramuscular injection, in intermittent courses | Epitalon timeline | | Semax | Semax (free base) | Intranasal only | Semax timeline | | KPV | KPV acetate | Topical and oral only | KPV timeline | | MOTS-c | MOTS-c acetate | Subcutaneous or intramuscular injection | MOTS-c timeline |
On this site, each of the six now shows the status "HHS interim policy (draft)."
The conditions
HHS's enforcement discretion applies only when every one of these is met: [2]
- The peptide is on Appendix A.
- The product matches the identity and the route limits in Appendix B.
- The bulk substance comes from an FDA-registered facility with a valid certificate of analysis that meets HHS's testing standard, covering identity, purity, potency, endotoxin, microbial limits, and impurities.
- The original manufacturer is FDA-registered and follows current good manufacturing practice, and its location is on the certificate. A reseller must validate the original manufacturer.
- The compounder reports serious adverse events and product quality problems to FDA MedWatch and to the states involved, and reports what it compounded.
- The label says: "This is a compounded drug product. Not for resale."
- The product has a single active ingredient. Blends and stacks are not covered.
- An oral form comes with documentation that the formulation achieves adequate oral bioavailability in humans.
- The only delivery device allowed is an FDA 510(k)-cleared syringe.
- Every other requirement of the Federal Food, Drug, and Cosmetic Act still applies, including a patient-specific prescription and no insanitary conditions.
What is not covered
Blends and stacks. The policy covers single-ingredient products only. The Wolverine stack (BPC-157 plus TB-500) is not covered, and neither are GLOW, KLOW, or any other multi-peptide product. [2]
Every other peptide. Only Appendix A counts. CJC-1295, ipamorelin, AOD-9604, selank, LL-37, melanotan II, PEG-MGF, dihexa, thymosin alpha-1, injectable GHK-Cu, and DSIP are not covered. [2]
Research-use-only products. Products labeled for research use only and sold for human use are still unlawful. HHS framed the policy as a controlled alternative to research-use-only peptides supplied by foreign manufacturers. [2]
Routes outside Appendix B. Semax injections, injectable KPV, and oral TB-500, for example, fall outside the route limits.
Dosing. The policy does not set or endorse any dose, and neither do we.
What did not change
None of the six is FDA approved. FDA has not reviewed their safety, effectiveness, or quality, and the policy does not add any of them to the 503A bulks list. [2] [5]
Our evidence grades are the same. A policy is not a study. Grades follow our methodology and stay where they were: BPC-157, TB-500, KPV, and MOTS-c are graded animal only, and semax and epitalon are graded human observational.
WADA status is the same. The WADA Prohibited List is separate from federal compounding policy. BPC-157 and the other covered peptides remain prohibited for tested athletes. [6]
State law still applies. Some states restrict these peptides. In August 2026, Mississippi's medical, nursing, and pharmacy boards barred licensed providers from prescribing research-grade peptides that are not FDA approved. [7] Louisiana has its own peptide law, Act 374. [8] Check your state in our state legal guides.
Timeline
- September 2023 to April 22, 2026: each of the six was in 503A Category 2. [2] [3]
- April 2026: FDA moved the six, with other peptides, to its list of nominations withdrawn by their nominators. [3]
- July 23 to 24, 2026: the six went before FDA's Pharmacy Compounding Advisory Committee. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). [2] [4] Our coverage of that meeting has the background.
- October 28, 2026: HHS filed the draft enforcement discretion policy for public inspection. [1]
- October 30, 2026: the notice was published in the Federal Register. [1]
- November 13, 2026: the two-week written comment period closes. [1]
HHS notes that FDA's future rulemaking may propose adding some or all of these peptides to the bulks list. No such rule has been proposed. [2]
How to comment
Anyone can submit a written comment on the draft policy. Go to regulations.gov, search for Docket No. HHS-OASH-2026-0496, and follow the comment instructions. Comments are accepted through November 13, 2026, two weeks after the notice was published in the Federal Register. [1]
What to check before you get a compounded peptide
If you and a clinician are considering one of the six, these checks follow the policy's own conditions: [2]
- A licensed 503A pharmacy in your state. Confirm the pharmacy's license with your state board of pharmacy, and check your state's rules in our legal guides.
- A real prescriber evaluation. The policy requires a patient-specific prescription. A checkout form is not an evaluation.
- A single-ingredient product. A blend or stack is outside the policy, and so is a route that Appendix B does not allow.
- A certificate of analysis. Ask for it. It should name the original FDA-registered manufacturer and its location, and show testing for identity, purity, potency, endotoxin, microbial limits, and impurities.
- The required label. It should read: "This is a compounded drug product. Not for resale."
A product that fails any of these checks is outside the policy. Each peptide page explains the evidence, the side effects reported, and what is actually offered, starting with BPC-157.
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
Pages referenced in this article
- IndexState legal guides
- PeptideBPC-157
- PeptideTB-500
- PeptideEpitalon
- PeptideKPV
- PeptideMOTS-c
- PeptideSemax
- RegulatoryBPC-157 regulatory timeline
- RegulatoryTB-500 regulatory timeline
- RegulatoryEpitalon regulatory timeline
- RegulatoryKPV regulatory timeline
- RegulatoryMOTS-c regulatory timeline
- RegulatorySemax regulatory timeline
- Page/blends/wolverine-stack
Frequently asked questions
Did RFK Jr. legalize peptides?
No. On October 28, 2026, HHS under Secretary Robert F. Kennedy Jr. released a draft enforcement discretion policy. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds BPC-157, TB-500, epitalon, KPV, MOTS-c, or semax when every condition in the policy is met. It is not a rule, not an FDA approval, does not add anything to the 503A bulks list, and is not binding on HHS or the public. [1] [2]
Is BPC-157 legal now?
BPC-157 is still not FDA approved and still not on the 503A bulks list. Under the draft policy, HHS says it will not take enforcement action against licensed compounding of single-ingredient BPC-157 by subcutaneous, intramuscular, oral, or topical routes, on a patient-specific prescription, when all of the policy's conditions are met. That is enforcement discretion, not a change in the law, and HHS may revisit it. State law still applies. [2] [5]
Which peptides are covered by the HHS policy?
Six, listed in Appendix A: BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500. Each is limited to the routes in Appendix B. No other peptide is covered. [2]
Is the Wolverine stack (BPC-157 and TB-500) covered?
No. The policy covers single active ingredient products only. Blends and stacks, including the Wolverine stack (BPC-157 plus TB-500), GLOW, and KLOW, are not covered, even though BPC-157 and TB-500 are each covered on their own. [2]
Can I buy BPC-157 online now?
Not as a research-use-only product. Research-use-only products sold for human use are still unlawful; HHS framed its policy as a controlled alternative to research-use-only peptides supplied by foreign manufacturers. The draft policy only addresses compounding by a state-licensed pharmacy, federal facility, or licensed physician for an individual patient with a prescription, under all of its conditions. [2]
Is semax injection covered?
No. Appendix B limits semax (free base) to intranasal use only. A semax product made for injection falls outside the policy. [2]
Is the HHS peptide policy permanent?
No. It is a draft. HHS says it may revisit the policy, in whole or in part, if a safety signal or product quality issue arises, and it lasts only until each peptide is addressed in a final rule on whether it is included on the 503A bulks list. Comments are open through November 13, 2026, two weeks after the notice was published in the Federal Register on October 30, 2026. [1] [2]
What about research-use-only peptides?
Nothing changed for them. Research-use-only products sold for human use are still unlawful. The policy only covers compounding from bulk substance made by an FDA-registered manufacturer with a tested certificate of analysis, by a licensed pharmacy, federal facility, or physician, on a patient-specific prescription. [2]
Are the other withdrawn peptides, like CJC-1295 and ipamorelin, covered?
No. CJC-1295, ipamorelin, AOD-9604, selank, LL-37, melanotan II, PEG-MGF, dihexa, thymosin alpha-1, injectable GHK-Cu, and DSIP are not in Appendix A, so the policy does not cover them. [2]
Does the HHS policy change anything for tested athletes?
No. The policy is about federal compounding enforcement. The WADA Prohibited List is separate, and BPC-157 and the other covered peptides keep their WADA status. [2] [6]
Sources
Numbered citations in the article point to these primary sources. PubMed entries link to the indexed abstract. Evidence grades follow our methodology.
- [1]Federal Register: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances; Notice of availability (HHS Office of the Secretary, FR Doc. 2026-22192, Docket No. HHS-OASH-2026-0496, published October 30, 2026)Federal Register, 2026
- [2]HHS: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendix A and Appendix B (draft, October 2026)2026
- [3]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B Category 2 lists and withdrawn nominations, content current as of April 22, 2026)FDA, 2026
- [4]FDA: Pharmacy Compounding Advisory Committee (July 23 to 24, 2026 meeting on peptide nominations)FDA, 2026
- [5]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA, 2026
- [6]WADA Prohibited List (sections S0 non-approved substances, S2 peptide hormones, and S4.4 metabolic modulators)WADA, 2026
- [7]Joint Statement Concerning the Prescribing of Non-FDA Approved (Research-Grade) Peptides (Mississippi Board of Nursing, Board of Pharmacy, State Board of Medical Licensure, August 19, 2026)2026
- [8]Louisiana Act No. 374 of 2026 (SB 253), enacting R.S. 37:23.52026
- [9]TIME: The Peptide Rush Has Begun (October 28, 2026)2026